share_log

Roth MKM Maintains Buy on First Wave BioPharma, Adjusts Price Target To $40

Benzinga ·  Jan 3 13:16

Roth MKM analyst Jonathan Aschoff maintains First Wave BioPharma (NASDAQ:FWBI) with a Buy, adjusts target to $40 from $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment